Ensysce Biosciences Announces Key Additions to Executive Team Ahead of Financing

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/opioid?src=hash" target="_blank"gt;#opioidlt;/agt;–Ensysce Biosciences Inc., a clinical phase drug development company with innovative technologies to curb prescription drug abuse and overdose, today announced two appointments to its senior management team. Kurt Schmidt has been appointed as the Company’s Chief Financial Officer. Mr. Schmidt is coming on board just as the company is rapidly progressing its lead TAAPTM product, PF614 through clinical development to help stem the opioid crisis that is facing America. G

Click to view original post

Advertise With Us